Kyntra Bio Posts Q1 $3.7M Revenue, $100M Cash Runway; FG-3246 Interim Analysis Slated Q4 2026
Kyntra Bio reported Q1 revenue of $3.7m, reduced net loss to $15.1m, and held $100.3m in cash, funding operations into 2028. The Phase 2 trial of FG-3246 in mCRPC is on track for a Q4 2026 interim analysis, and its Phase 3 roxadustat protocol is finalizing for H2 2026 start.
1. Q1 2026 Financial Results
In Q1 2026, Kyntra Bio generated $3.7 million in revenue, up from $2.7 million a year prior, and reported a net loss of $15.1 million, or $3.74 per share, compared with a $16.8 million loss, or $4.15 per share, in Q1 2025.
2. FG-3246 and Roxadustat Milestones
The Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer continues enrolling, targeting a fourth-quarter 2026 interim analysis, while combination data showed a median radiographic progression-free survival of 7.0 months overall and 10.1 months in single-ARPI-progressed patients. The pivotal Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes is being finalized for a second-half 2026 start.
3. Cash Position and Runway
As of March 31, 2026, the company held $100.3 million in cash, equivalents, investments, and accounts receivable, which it expects will fund operations into 2028.
4. Upcoming Webcast
Management will host a conference call and webcast today at 5:00 PM ET to discuss these results and provide a business update, followed by a live Q&A session.